Your Article Summary
See Latest ArticlesPossibility of a rebound phenomenon following antiplatelet therapy withdrawal: A look at the clinical and pharmacological evidence
Pharmacology & Therapeutics, 06/24/09
Lordkipanidze M et al. - This review article describes the thrombotic risks associated with discontinuing antiplatelet therapy and the bleeding risks associated with continuing these drugs. By integrating the current understanding of the pharmacology of antiplatelet agents and the kinetics of platelet function recovery, this article unveils the possibility of a pharmacological rebound phenomenon which could lead to adverse ischemic events, and supports the warning against premature discontinuation of antiplatelet drugs issued in current guidelines.
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Chitosan-tripolyphosphate nanoparticles as a possible skin drug delivery system for aciclovir with enhanced stability
Journal of Pharmacy and Pharmacology, 12/15/09
Novel TNF antagonists for the treatment of rheumatoid arthritis
Expert Opinion on Investigational Drugs, 12/15/09
Genentech and Biogen Idec Announce Positive Results From First Phase III Trial of Ocrelizumab in Rheumatoid Arthritis
Genentech, 12/15/09
Today in Pharmacokinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Safety of Oseltamivir Compared With the Adamantanes in Children Less Than 12 Months of Age
The Pediatric Infectious Disease Journal, 12/15/09
Evaluating pharmacokinetics and pharmacodynamics of intravenous busulfan in pediatric patients receiving bone marrow transplantation
Pediatric Transplantation, 12/15/09
'Party pill' drugs - BZP and TFMPP
New Zealand Medical Journal, 12/14/09